학술논문
Overall survival with [177 Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Document Type
Article
Author
Hofman, M.S.; Sandhu, S.; Iravani, A.; Buteau, J.P.; Azad, A.A.; Williams, S.G.; Scott, A.M.; Lee, S.-T.; Emmett, L.; Joshua, A.M.; Lin, P.; Goh, J.C.; Pattison, D.A.; Martin, A.J.; Tan, T.H.; Kirkwood, I.D.; Ng, S.; Francis, R.J.; Redfern, A.D.; Macdonald, W.; Gedye, C.; Rutherford, N.K.; Weickhardt, A.; Kwan, E.M.; Ramdave, S.; Guminski, A.; Hsiao, E.; Chua, W.; Zhang, A.Y.; Stockler, M.R.; Davis, I.D.; Akhurst, T.; Alipour, R.; Bailey, D.; Banks, P.; Beaulieu, A.; Campbell, L.; Crumbaker, M.; Dhiantravan, N.; Hamid, A.; Haskali, M.; Hung, T.; Kong, G.; Lawrence, N.; Lewin, J.; McCarthy, M.; Moodie, K.; Murphy, D.; Nguyen, A.; Pook, D.; Ravi Kumar, A.; Roach, P.; Roselt, P.; Saghebi, J.; Schembri, G.; Spain, L.; Subramaniam, S.; Thang, S.P.; Thomas, P.; Tran, B.; Wallace, R.; Yip, S.
Source
In: The Lancet Oncology . (The Lancet Oncology, January 2024, 25(1):99-107)
Subject
Language
English
ISSN
14745488
14702045
14702045